






# Go Beyond the Limits of Standard Exomes with Genome-First Exome Analysis

By anchoring Exome Analysis in whole-genome sequencing (WGS) and multiomic integration, MyOme uncovers more answers and offers a seamless, cost-effective path to full genome insights.



## MyOme's Unified, Multiomic Platform


Rare Disease Exome Analysis integrates three powerful technologies into a single workflow to broaden diagnostic reach without the need for multiple, fragmented orders.<sup>1,2</sup>

<p><b>PCR-Free WGS</b></p>  <p>Ensures uniform, unbiased coverage to detect CNVs, SNVs, and indels across both coding and non-coding regions*</p>	<p><b>Built-in mitochondrial DNA (mtDNA) Sequencing</b></p>  <p>Detects mtDNA variants not typically included in standard exome testing</p>	<p><b>Automated Long-Read Sequencing (LRS)</b></p>  <p>Analyzes complex TREs and methylation signatures to aid in variant resolution and interpretation</p>
--	---	---

\*CNVs: Copy Number Variants, SNVs: Single Nucleotide Polymorphisms, Indels: small insertions/deletions, mtDNA: Mitochondrial DNA, TREs: Tandem Repeat Expansions

## Bridge the Diagnostic Gap


MyOme's comprehensive, genome-first platform expands variant detection beyond standard exome testing, capturing a wider range of variant types and genetic features—all from a single sequence.






## Streamlined, Cost-Effective Upgrade to Genome

With MyOme Zenith Exome, whole-genome data is captured from the start, allowing a seamless transition from exome to genome analysis—saving critical time and reducing costs for families seeking answers.



## Real-World Impact

Equipped with multiomic, genome-first Exome Analysis, MyOme uncovered a diagnostic variant missed by another lab's exome test, empowering a family with a long-awaited diagnosis.



**MyOme Rare Disease Exome Analysis delivers more.**

Learn more at [myome.com/our-tests/diagnostic](https://www.myome.com/our-tests/diagnostic).

Tests were developed, and their performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and College of American Pathologist (CAP) accredited to perform high complexity clinical laboratory testing. These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test results should always be interpreted by a clinician in the context of clinical and familial data with the availability of genetic counseling when appropriate. MyOme is not responsible for the content or accuracy of third-party websites.